Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists.

[1]  Xia Li,et al.  Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[2]  A. Newman,et al.  Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[3]  Martin Stahl,et al.  Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP , 2006, Journal of neurochemistry.

[4]  R. Baldwin,et al.  Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. , 2006, Journal of medicinal chemistry.

[5]  M. Tranfaglia,et al.  Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP , 2005, Neuropharmacology.

[6]  P. Jeffrey Conn,et al.  A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric Modulators , 2005, Molecular Pharmacology.

[7]  T. Kamenecka,et al.  Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[8]  M. Bear,et al.  Therapeutic implications of the mGluR theory of fragile X mental retardation , 2005, Genes, brain, and behavior.

[9]  Karolina Nilsson,et al.  Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. , 2005, Current topics in medicinal chemistry.

[10]  S. Buchwald,et al.  Catalysts for Suzuki-Miyaura coupling processes: scope and studies of the effect of ligand structure. , 2005, Journal of the American Chemical Society.

[11]  C. Swanson,et al.  Metabotropic glutamate receptors as novel targets for anxiety and stress disorders , 2005, Nature Reviews Drug Discovery.

[12]  N. Cosford,et al.  Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. , 2004, Journal of medicinal chemistry.

[13]  R. Spanagel,et al.  mGluR5 Antagonist MPEP Reduces Ethanol-Seeking and Relapse Behavior , 2004, Neuropsychopharmacology.

[14]  Andrea M Nolan,et al.  Up-regulation of metabotropic glutamate receptor subtypes 3 and 5 in spinal cord in a clinical model of persistent inflammation and hyperalgesia , 2003, Pain.

[15]  P. Malherbe,et al.  Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. , 2003, Molecular pharmacology.

[16]  F. Gasparini,et al.  The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice , 2003, Psychopharmacology.

[17]  J. Nadeau,et al.  l-Homocysteine Sulfinic Acid and Other Acidic Homocysteine Derivatives Are Potent and Selective Metabotropic Glutamate Receptor Agonists , 2003, Journal of Pharmacology and Experimental Therapeutics.

[18]  Mark Washburn,et al.  3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. , 2003, Journal of medicinal chemistry.

[19]  P. Popik,et al.  Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist , 2002, Neuropharmacology.

[20]  Fabrizio Gasparini,et al.  Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. , 2002, Current opinion in pharmacology.

[21]  F. Conquet,et al.  Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice , 2001, Nature Neuroscience.

[22]  F. Gasparini,et al.  Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.

[23]  F. Gasparini,et al.  Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. , 2001, Farmaco.

[24]  F. Gasparini,et al.  The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.

[25]  S. Buchwald,et al.  Highly Active Palladium Catalysts for Suzuki Coupling Reactions , 1999 .

[26]  N. Miyaura,et al.  Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters , 1995 .

[27]  C. Geula,et al.  Asymmetric behavior induced by enkephalinergic agents in the basal ganglia , 1985, Pharmacology Biochemistry and Behavior.

[28]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.